New hope for lupus skin flares? drug shows promise in early trial
NCT ID NCT03288324
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug tofacitinib in 13 young adults aged 18 to 45 with moderate to severe lupus skin disease. The goal was to see if the drug is safe and can reduce skin symptoms. Participants took the drug for up to 76 weeks, and doctors measured how well it worked using a skin severity score.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS LUPUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
MetroHealth Medical Center
Cleveland, Ohio, 44109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new biologic tame lupus flares?
- Could a single injection tame lupus and Sjögren's?
- Can a single infusion tame tough lupus?
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.
- Can genetics and environment explain lupus in the gullah population?
- Can a smartphone app bridge the lupus care gap for women of color?